Evidence map›Paper›PMID 8643438›Full record

ReviewProceedings of the National Academy of Sciences of the United States of America1996

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain.

R B Darnell

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02533895 (Monocyte-derived Dendritic Cells Loaded With Tumour Cell Lysates for the Treatment of Refractory Solid Tumours of Childhood), which is not on this map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02533895 phase1completednot on this mapstarted 2000, after this paper: background citation

Monocyte-derived Dendritic Cells Loaded With Tumour Cell Lysates for the Treatment of Refractory Solid Tumours of Childhood

TypeinterventionalSponsorActivartis BiotechRan2000 to 2015Enrolled67ConditionsChildhood Solid TumorArmsAV0113 DC-CIT, Data evaluation
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.Proceedings of the National Academy of Sciences of the United States of America · 2001
    Trial
  4. Review
  5. Article
  6. Review
  7. NOVA1 acts as an oncogenic RNA-binding protein to regulate cholesterol homeostasis in human glioblastoma cells.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Review
  9. Article
  10. Paraneoplastic neurological syndrome: growing spectrum and relevance.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Paraneoplastic neurological syndromes: clinical presentations and management.Therapeutic advances in neurological disorders · 2021
    Review
  17. Paraneoplastic syndromes in cholangiocarcinoma.World journal of hepatology · 2020
    Review
  18. Article
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

R B DarnellLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, 10021, USA.
Rockefeller University · US

Funding

NEUROLOGY AND THE MOLECULAR ROLE OF N-RBPS IN THE BRAINR01NS034389 · NINDS · ROCKEFELLER UNIVERSITY · PI DARNELL, ROBERT B · 1995 to 2016
$6.3M
NINDS NIH HHS R01 NS34389
6 · The paper itself

Abstract

Paraneoplastic neurologic disorders (PNDs) are believed to be autoimmune neuronal degenerations that develop in some patients with systemic cancer. A series of genes encoding previously undiscovered neuronal proteins have been cloned using antiserum from PND patients. Identification of these onconeural antigens suggests a reclassification of the disorders into four groups: those in which neuromuscular junction proteins, nerve terminal/vesicle-associated proteins, neuronal RNA binding proteins, or neuronal signal-transduction proteins serve as target antigens. This review considers insights into basic neurobiology, tumor immunology, and autoimmune neuronal degeneration offered by the characterization of the onconeural antigens.

Indexed as

Antigens, NeoplasmAutoimmune DiseasesHumansModels, NeurologicalNerve DegenerationNerve Tissue ProteinsNervous System DiseasesNeuroimmunomodulationParaneoplastic SyndromesAntigens, NeoplasmNerve Tissue Proteins

Identifiers

PMID8643438
PMCPMC39311
OpenAlexW2012403244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.